Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Blum

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmNaveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Leukemia & Lymphoma|September 4, 2023
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemiaBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.
The Journal of Clinical Investigation|October 25, 2016
MicroRNA-29b mediates altered innate immune development in acute leukemiaBethany L Mundy-Bosse, Steven D Scoville, Li Chen, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Blood|December 18, 2007
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemiaShujun Liu, Zhongfa Liu, Zhiliang Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Blood|March 26, 2016
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsSumithira Vasu, Shun He, Carolyn Cheney, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmNaveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Leukemia & Lymphoma|September 4, 2023
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemiaBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.
The Journal of Clinical Investigation|October 25, 2016
MicroRNA-29b mediates altered innate immune development in acute leukemiaBethany L Mundy-Bosse, Steven D Scoville, Li Chen, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Blood|December 18, 2007
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemiaShujun Liu, Zhongfa Liu, Zhiliang Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemiaXiaomeng Huang, Sebastian Schwind, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2005
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activityGuido Marcucci, Wendy Stock, Guowei Dai, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Blood|March 26, 2016
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsSumithira Vasu, Shun He, Carolyn Cheney, et al.
Pageof 12